William Barton / Shutterstock.com

29 January 2025NewsAmericasMuireann Bolger

GSK seeks damages hike in ‘skinny label’ case

Complex legal battle concerns ‘skinny label’ strategy used by generic drug makers, prompting a $235 million award | Pharma giant looks for enhanced damages due to ‘wilful infringement’, while opponent wants another trial.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Effects of GSK v Teva ripple after SCOTUS denies cert

23 May 2023 Despite one judge’s insistence that the case was “narrow and fact dependent”, GSK v Teva could have wide-reaching implications for generic drugs, biosimilars, and how skinny labels are read, say Chad Landmon, Ross Blau, Gulrukh Haroon of Axinn, Veltrop & Harkrider.

article

Teva loses plea against GSK’s $235m ‘skinny label’ win

16 May 2023 The US Supreme Court knocks back Teva’s challenge to GSK’s damages win | Decision issued despite US solicitor general warning that the earlier decision ‘threatens significant harm’ to the market.

More on this story

Effects of GSK v Teva ripple after SCOTUS denies cert

23 May 2023 Despite one judge’s insistence that the case was “narrow and fact dependent”, GSK v Teva could have wide-reaching implications for generic drugs, biosimilars, and how skinny labels are read, say Chad Landmon, Ross Blau, Gulrukh Haroon of Axinn, Veltrop & Harkrider.

article

Teva loses plea against GSK’s $235m ‘skinny label’ win

16 May 2023 The US Supreme Court knocks back Teva’s challenge to GSK’s damages win | Decision issued despite US solicitor general warning that the earlier decision ‘threatens significant harm’ to the market.

More on this story

Effects of GSK v Teva ripple after SCOTUS denies cert

23 May 2023 Despite one judge’s insistence that the case was “narrow and fact dependent”, GSK v Teva could have wide-reaching implications for generic drugs, biosimilars, and how skinny labels are read, say Chad Landmon, Ross Blau, Gulrukh Haroon of Axinn, Veltrop & Harkrider.

article

Teva loses plea against GSK’s $235m ‘skinny label’ win

16 May 2023 The US Supreme Court knocks back Teva’s challenge to GSK’s damages win | Decision issued despite US solicitor general warning that the earlier decision ‘threatens significant harm’ to the market.

More features

GSK escalates mRNA COVID-19 vaccine dispute

Smart ringleader: Could Ōura’s market dominance be under threat?

The flaw that landed Sanofi a win in the rare disease space

Roche resolves cancer test dispute with Stanford affiliated startup

Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory

UK firm expands in Germany with more litigation hires

Sandoz blocked by UK court from seeking Xarelto profits

An update on patenting in Ukraine, Russia and Eurasia